Abstract 6701: BPR-30901649, a Next-Generation Angiotensinogen siRNA, Achieves Ultra-Durable Target Silencing and Sustained Blood Pressure Reduction Through 20 Weeks in Hypertensive Non-Human Primates
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.6701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Yu Chen und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Hypertension affects over 1.3 billion adults globally, and poor long-term adherence to daily oral therapies drives inadequate blood pressure (BP) control. RNA interference (RNAi) targeting hepatic angiotensinogen (AGT) has emerged as a clinically advanced approach, with single-dose BP lowering demonstrated through six months. Further extension of durability could enable twice-yearly or less frequent dosing and substantially improve chronic hypertension management. Research Questions / Hypothesis: We hypothesized that BPR-30901649, a novel, liver-targeted AGT siRNA with an optimized molecular design, would demonstrate superior potency and extended durability compared to an advanced clinical benchmark, translating into sustained, dose-dependent BP lowering with a wide safety margin.
Methods
Potency was evaluated head-to-head in humanized AGT transgenic mice receiving a single subcutaneous (SC) dose of BPR-30901649, an advanced clinical benchmark siRNA, or vehicle (n=6). Translational efficacy and long-term pharmacodynamics were validated in hypertensive cynomolgus monkeys randomized to receive a single SC dose of BPR-30901649 (1.5 or 3.0 mg/kg), or vehicle (n=4). Serum AGT levels and systolic blood pressure (SBP) were tracked for up to 20 weeks. IND-enabling safety studies were conducted in rats and NHPs.
Results
In humanized mice, BPR-30901649 achieved significantly deeper serum AGT knockdown (KD) versus the benchmark. In hypertensive NHPs, a single SC injection of BPR-30901649 produced rapid, dose-dependent, and remarkably sustained AGT suppression. Peak AGT reduction reached 98% by week 5 in both dose groups. Notably, >95% AGT knockdown was maintained for 9 weeks (1.5 mg/kg) and 10 weeks (3.0 mg/kg) , while >90% knockdown persisted for 12 weeks and over 18 weeks, respectively (Fig.1A). This ultra-durable target engagement translated to potent and sustained SBP lowering. Maximal SBP reductions occurred at week 7 for 1.5 mg/kg (–17.9%; –25.5 mmHg) and week 6 for 3.0 mg/kg (–21.6%; –31.5 mmHg). At week 20, significant SBP reductions of -14.2% (-20.3 mmHg) and -17.3% (-25.3 mmHg) persisted in low- and high-dose groups, respectively (Fig.1B). In IND-enabling repeat-dose toxicology studies, the No-Observed-Adverse-Effect Level (NOAEL) was established at 200 mg/kg in both rats and NHPs, with no evidence of hepatotoxicity or systemic toxicity.
Conclusions
BPR-30901649 outperformed an advanced clinical-stage AGT siRNA benchmark in vivo , producing durable AGT silencing and sustained SBP reduction through 20 weeks after a single dose in a translational NHP hypertension model. With a NOAEL of 200 mg/kg and a wide preclinical safety margin, these data support clinical development of BPR-30901649 as a candidate for twice-yearly hypertension therapy.
Zitieren
APA
Chen, Y., LING, Y., Lu, J., duan, J., CHENG, X., & huang, H. (2026). Abstract 6701: BPR-30901649, a Next-Generation Angiotensinogen siRNA, Achieves Ultra-Durable Target Silencing and Sustained Blood Pressure Reduction Through 20 Weeks in Hypertensive Non-Human Primates. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6701
Vancouver
Chen Y, LING Y, Lu J, duan J, CHENG X, huang H. Abstract 6701: BPR-30901649, a Next-Generation Angiotensinogen siRNA, Achieves Ultra-Durable Target Silencing and Sustained Blood Pressure Reduction Through 20 Weeks in Hypertensive Non-Human Primates. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6701
BibTeX
@article{Chen2026,
author = {Chen, Yu and LING, YANG and Lu, Jiaqi and duan, jiachuan and CHENG, XIWEN and huang, haoxi},
title = {Abstract 6701: BPR-30901649, a Next-Generation Angiotensinogen siRNA, Achieves Ultra-Durable Target Silencing and Sustained Blood Pressure Reduction Through 20 Weeks in Hypertensive Non-Human Primates},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.6701}
}
EUVIMED